{"id":"jyb1904","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL6068159","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"S1P1 receptor antagonists like JYB1904 are being investigated for their potential to treat various autoimmune diseases by inhibiting the S1P1 receptor, which plays a crucial role in lymphocyte trafficking and immune response.","oneSentence":"JYB1904 is a small molecule targeting the S1P1 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:39.796Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07459452","phase":"PHASE2","title":"Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-04","conditions":"Perennial Allergic Rhinitis","enrollment":135},{"nctId":"NCT07220811","phase":"PHASE2","title":"Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy","status":"RECRUITING","sponsor":"RAPT Therapeutics, Inc.","startDate":"2025-10-22","conditions":"Ig-E Mediated Food Allergy","enrollment":100},{"nctId":"NCT07402213","phase":"PHASE3","title":"Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2026-03-31","conditions":"Chronic Spontaneous Urticaria","enrollment":180},{"nctId":"NCT06438757","phase":"PHASE2","title":"Trial of JYB1904 in Patients With Allergic Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jemincare","startDate":"2024-06-19","conditions":"Allergic Asthma","enrollment":69},{"nctId":"NCT06509334","phase":"PHASE2","title":"Trial of JYB1904 in Chronic Spontaneous Urticaria.","status":"RECRUITING","sponsor":"Jemincare","startDate":"2024-08-04","conditions":"Chronic Spontaneous Urticaria","enrollment":135},{"nctId":"NCT05449535","phase":"PHASE1","title":"Study of JYB1904 (an Anti-immunoglobulin E Antibody) in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Jemincare","startDate":"2022-05-07","conditions":"Healthy","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["JYB1904 Injection"],"phase":"phase_3","status":"active","brandName":"JYB1904","genericName":"JYB1904","companyName":"Jemincare","companyId":"jemincare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JYB1904 is a small molecule targeting the S1P1 receptor. Used for Relapsing multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}